8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione

8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Basic information
Product Name:8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Synonyms:8-BroMo-7-(2-butyn-a-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione;8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquin-azolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dion;8-BroMo-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-1H-purine-2,6(3H,7H)-dione;1H-Purine-2,6-dione,8-broMo-7-(2-butynyl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-;Linagliptin interMediate F;1-[(4-Methylquinazolin-2-yl)Methyl]-3-Methyl-7-(2-butin-1-yl)-8-broMoxanthine;1H-Purine-2,6-dione, 8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-;Iinagliptin Intermediate3
CAS:853029-57-9
MF:C20H17BrN6O2
MW:453.29
EINECS:922-028-0
Product Categories:Intermediates;853029-57-9
Mol File:853029-57-9.mol
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Structure
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Chemical Properties
Melting point >255°C (dec.)
Boiling point 602.9±65.0 °C(Predicted)
density 1.55
storage temp. under inert gas (nitrogen or Argon) at 2-8°C
solubility DMSO (Slightly, Heated, Sonicated), Methanol (Very Slightly, Heated, Sonicated)
pka2.34±0.50(Predicted)
form Solid
color White to Pale Yellow
Safety Information
MSDS Information
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Usage And Synthesis
Uses8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione is an intermediate used to prepare selective inhibitors of dipeptidyl peptidase 4 (DPP4) for potential use in the treatment of type 2 diabetes.
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Preparation Products And Raw materials
Cyclopropanamine,2-(3,4-difluorophenyl)-(1R,2S) -(2R,3R)-2,3-dihydroxybutanedioate (1:1) Canagliflozin DESETHYL HYDROXY CHLOROQUINE Linagliptin impurity 15 Linagliptin Impurity F Tetrahydro-2,2-dimethyl-4,7-methano-6H-1,3-dioxolo[4,5-d][1,2]oxazine-6-carboxylic acid phenylmethyl ester Hydroxychloroquine Sulfate EP Impurity A (1R trans)-2-(3,4-difluorophenyl)cyclopropane amine 8-bromo-7-(but-2-ynyl)-3-methyl-1H-purine-2,6(3H,7H)-dione Linagliptin iMpurity E Tert-butyl((3s)-1-(7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-2,6-dioxo-2,3,4,5,6,7-hexahydro-1h-purin-8-yl)piperidin-3-yl)carbaMate Linagliptin Linagliptin iMpurity G Linagliptin Impurity K 3-(R)-Piperidinyl PhthaliMide D-(-)-tartaric acid Linagliptin Impurity D Rivaroxaban Hydroxychloroquine O-Sulfate

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.